Physician profile
Shang Wu
NPI 1336228253
$202,631.00
in general payments reported to CMS, 2019-2025
24 companies · $25K in 2025
The $25K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $16K · 2021: $39K · 2022: $30K · 2023: $21K · 2024: $34K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Food and Beverage: $7,297 · Honoraria: $5,175 · Travel and Lodging: $1,962 · Gift: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,016.00 |
| Food and Beverage | $7,297.29 |
| Honoraria | $5,175.00 |
| Travel and Lodging | $1,961.57 |
| Gift | $245.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $106,501.30 | 2019-2025 | Vemlidy, Livdelzi |
| Abbvie INC. | $63,004.74 | 2019-2025 | Creon, Linzess, Viberzi |
| Phathom Pharmaceuticals, INC. | $13,384.14 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $9,826.76 | 2024-2025 | Iqirvo |
| Allergan, INC. | $5,683.80 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $1,109.60 | 2019-2023 | Ocaliva |
| Shionogi INC | $873.95 | 2019 | |
| Braintree Laboratories, INC. | $527.93 | 2019-2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.00 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $311.46 | 2024-2025 | Resmetirom, Rezdiffra |
| Ironwood Pharmaceuticals, INC | $279.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $158.83 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.09 | 2019-2023 | Entyvio |
| Orphalan INC | $120.90 | 2023-2025 | Cuvrior |
| Novo Nordisk INC | $75.95 | 2025 | Wegovy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $53.93 | 2025 | Xermelo |
| Nestle Healthcare Nutrition INC. | $49.42 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $48.33 | 2022 | |
| Redhill Biopharma INC. | $34.77 | 2020 | |
| Albireo Pharma, INC. | $17.99 | 2024 | Iqirvo |
| Capsovision, INC. | $17.44 | 2025 | Capsocam Plus |
| Amgen INC. | $16.45 | 2025 | Repatha |
| Ferring Pharmaceuticals INC. | $12.26 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shang Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.